Marker Therapeutics is expected to report a narrower loss of $0.22 per share on revenue of approximately $0.60 million, while the stock currently trades at $1.12 relative to a $7.87 analyst price target. The single most important factor for investors this quarter is the anticipated interim clinical data update from the Phase 1 APOLLO study evaluating lead asset MT-601 in lymphoma.
Management previously demonstrated a 66% objective response rate in this study, and analysts are looking for updates on response durability and the scheduled initiation of a company-sponsored pancreatic cancer program. Maintaining clinical momentum remains vital as the pre-commercial biotech manages a cash runway currently projected to support operations through the end of 2026.